Table 1 shows the participants’ baseline demographic and laboratory data according to treatment response at 24 weeks after PEG-IFN discontinuation. Compared to patients with poor response (in terms of lack of an SVR), patients who achieved SVR were older, had lower pre-treatment serum HCV RNA levels, and were less likely to have HCV genotype 1, advanced liver fibrosis, and the unfavorable IL28B rs12979860 CT/TT genotypes. The gene discussed is IFNL3; the disease is Hepatic fibrosis.